Literature DB >> 20036730

Inability to confirm estrogenicity of the heterocyclic amine PhIP in two in vitro assays.

Richard M Evans1, Sinikka Rahte, Andreas Kortenkamp.   

Abstract

2-Amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine (PhIP) is a heterocyclic amine which is found in food after cooking and which is a known mutagen. Reports from several laboratories have proposed that PhIP has estrogenic activity, which would classify PhIP as a xenoestrogen with human exposure via food. We tested PhIP in two cell-based assays for estrogenicity, both based on human cell lines but utilising different outcome measures: ERLUX (reporter-gene activation) and ESCREEN (cell proliferation). PhIP was inactive in both assays at concentrations spanning the picomolar to micromolar range. To eliminate supplier differences as an explanation for the disparity between these results and positive findings in the literature, we purchased PhIP from three suppliers and found no detectable estrogenic activity in any batch. (1)H NMR spectroscopy confirmed the chemical identity of the tested stock solutions. Correct assay performance was confirmed by including positive and vehicle controls on every assay plate, and by demonstrating the expected responses to a panel of known estrogens (estradiol, bisphenol A, and genistein). Our results differ from those in the literature and, whilst the exact reason for this is unknown, we discuss possible explanations of the disparity. Our results provide no in vitro evidence for the classification of PhIP as an estrogen. Copyright 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20036730     DOI: 10.1016/j.tiv.2009.12.017

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  2 in total

1.  Additive mixture effects of estrogenic chemicals in human cell-based assays can be influenced by inclusion of chemicals with differing effect profiles.

Authors:  Richard Mark Evans; Martin Scholze; Andreas Kortenkamp
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

2.  Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms.

Authors:  Céline Gérard; Mélanie Mestdagt; Ekaterine Tskitishvili; Laudine Communal; Anne Gompel; Elisabete Silva; Jean-François Arnal; Françoise Lenfant; Agnès Noel; Jean-Michel Foidart; Christel Péqueux
Journal:  Oncotarget       Date:  2015-07-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.